（同仁堂公告） 近日，同仁堂（600085）发布公告称，公司分支机构同仁堂制药厂收到加拿大卫生部核准签发的《产品 许可证（三类）》，儿感清口服液、锁阳固精丸、人参健脾丸、大黄虫丸获得加拿大产品注册。 公告同样指出，这些产品若在加拿大销售，还需完成包括生产场地的加拿大生产质量体系认证等行政审 批事项，该等审批可能存在一定不确定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 ...

政策动向 国家药监局药审中心发布《罕见病用化学药物药学研究指导原则（试行）》 2月24日，中国药审官微发布消息显示，为落实《国务院办公厅关于全面深化药品医疗器械监管改革促 进医药产业高质量发展的意见》（国办发〔2024〕53号），加大对罕见病药物研发的支持力度，进一步 完善罕见病药物技术指导原则体系，鼓励和加速推动罕见病药物研发上市，在国家药品监督管理局的部 署下，药审中心组织制定了《罕见病用化学药物药学研究指导原则（试行）》，自发布之日起施行。 药械审批 恒瑞医药：1类创新药SHR-1918注射液获受理并纳入优先审评程序 2月24日，恒瑞医药(600276.SH)公告称，公司子公司北京盛迪医药有限公司收到国家药监局下发的《受 理通知书》，公司1类创新药SHR-1918注射液的药品上市许可申请获受理，且已被纳入优先审评程序。 该药品用于治疗成人和12岁及以上的未成年人纯合子家族性高胆固醇血症（HoFH）患者。SHR-1918注 射液是公司自主研发的血管生成素样蛋白3（ANGPTL3）单克隆抗体，通过抑制ANGPTL3的活性，从 而降低血清中的甘油三酯（TG）和LDL-C水平。截至目前，相关项目累计研发投入约2 ...

同仁堂制药厂产品儿感清口服液、锁阳固精丸、人参健脾丸、大黄䗪虫丸取得加拿大卫生部颁发的《产 品许可证(三类)》系产品上市许可。上述产品若拟在加拿大销售，后续还需根据加拿大卫生部法规要 求，完成包括但不限于对生产场地的加拿大生产质量体系认证等行政审批事项，该等审批可能存在一定 不确定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 智通财经APP讯，同仁堂(600085.SH)发布公告，公司分支机构北京同仁堂股份有限公司同仁堂制药厂 (以下简称同仁堂制药厂)收到加拿大卫生部核准签发的《产品许可证(三类)》，同仁堂制药厂产品儿感 清口服液、锁阳固精丸、人参健脾丸、大黄䗪虫丸获得加拿大产品注册。 ...

同仁堂制药厂产品儿感清口服液、锁阳固精丸、人参健脾丸、大黄虫丸取得加拿大卫生部颁发的《产品 许可证(三类)》系产品上市许可。上述产品若拟在加拿大销售，后续还需根据加拿大卫生部法规要求， 完成包括但不限于对生产场地的加拿大生产质量体系认证等行政审批事项，该等审批可能存在一定不确 定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 同仁堂（600085）(600085.SH)发布公告，公司分支机构北京同仁堂股份有限公司同仁堂制药厂(以下简 称同仁堂制药厂)收到加拿大卫生部核准签发的《产品许可证(三类)》，同仁堂制药厂产品儿感清口服 液、锁阳固精丸、人参健脾丸、大黄虫丸获得加拿大产品注册。 ...

每经AI快讯，2月24日，同仁堂（600085）(600085.SH)公告称，公司分支机构同仁堂制药厂收到加拿大 卫生部核准签发的《产品许可证(三类)》，儿感清口服液、锁阳固精丸、人参健脾丸、大黄虫丸获得加 拿大产品注册。但这些产品若在加拿大销售，还需完成包括生产场地的加拿大生产质量体系认证等行政 审批事项，该等审批可能存在一定不确定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 ...

同仁堂聚焦"满足行业需求的中药质控体系缺乏"的行业痛点，与北京中医药大学合作，在功效物质明 晰、质量控制指标筛选等方面建立了一系列专有技术和方法，系统阐明了大黄、人参等中药饮片所含的 化学成分以及体内代谢转化成分，进而精准表征了大黄蛰虫丸、人参养荣丸、人参健脾丸等中药复方的 物质基础，阐明了中药质量形成机理。通过内控标准提升和技术升级改造，促进了产品质量的进一步提 升。 近日，中华中医药学会公示了2025年度中华中医药学会科学技术奖评审结果。由北京中医药大学高晓燕 教授牵头，联合同仁堂等6家单位共同申报的《中药功效物质高效发现技术体系创新与产业化应用》项 目获科技进步三等奖。 阐明中药功效物质是构建中药整体质控标准体系、保障临床用药和产业发展的关键。几十年来，随着中 药现代化进程的发展，在中药功效成分研究领域取得了可喜进展，但依然无法克服其片面性、假阳性、 低效性等问题，制约了中药标准化和国际化。该项目是以中医药传承与创新发展的国家重大发展战略为 牵引，针对制约中药功效物质发现全面性和准确性的若干技术问题，朝向中药化学成分高效解析、功效 指标精准量化和功效物质准确辨识三个关键环节开展研究：利用高分辨质谱技术， ...

Core Viewpoint - The company is committed to enhancing quality and efficiency while providing returns to shareholders through its 2024 and 2025 action plans, focusing on core business areas and improving production capabilities [1][2]. Group 1: Focus on Core Business - The company aims to enhance brand strength, product quality, and service capabilities, achieving an industrial main revenue of 2.645 billion yuan in the first half of 2025, a year-on-year increase of 0.87%, with sales of the fast-acting heart-saving pill growing by 52.28% [1][2]. - The company has initiated a public welfare campaign for the fast-acting heart-saving pill and successfully hosted the 11th Traditional Chinese Medicine Material Base Sharing Conference [1]. Group 2: Enhancing Production Quality - The company has established 46 procurement standards for traditional Chinese medicine materials that exceed the Chinese Pharmacopoeia standards and is working on the "Quality Standards for Traditional Chinese Medicine Materials (2025)" [2]. - The company has launched several product innovations, including age-friendly product adaptations and the development of new products for sensitive skin, which were launched in July [2]. Group 3: Shareholder Returns - The company distributed a cash dividend of 12.80 yuan per 10 shares, totaling 986 million yuan, with a cumulative cash dividend of 5.117 billion yuan since its listing in 2001, reflecting an average dividend payout ratio of 50.69% [4]. - The company plans to continue enhancing shareholder returns while adhering to regulatory guidelines on cash dividends [4]. Group 4: Investor Communication - The company has improved its information disclosure practices, receiving an A-level rating for information disclosure for 2023-2024, and has organized various activities to enhance investor engagement [5]. - The company has opened new channels for shareholder participation in governance and feedback, including a dedicated email for the chairman [5]. Group 5: Governance and Compliance - The company has updated its governance policies to protect investor rights, particularly for minority shareholders, and has implemented new management systems [6]. - The company has introduced incentive programs for key personnel to align their interests with those of shareholders [6][8].

Core Viewpoint - The company, Darentang, reported a significant increase in net profit by 193% to 1.928 billion yuan, while revenue plummeted by 33.15% to 2.651 billion yuan, marking the third consecutive year of revenue decline [1] Financial Performance - Net profit surged to 1.928 billion yuan, primarily supported by the sale of key assets [1] - Revenue fell to 2.651 billion yuan, continuing a downward trend with projected declines of 0.33% and 11.14% for 2023 and 2024 respectively [1] - The sale of a 12% stake in Tianjin Schering Pharmaceutical generated a post-tax net gain of 1.308 billion yuan, significantly boosting net profit [1] - Excluding this asset sale, the adjusted net profit was only 596 million yuan, reflecting a year-on-year decline of 5.99% [1] Asset Management - The divestment of Tianjin Schering, a key profit contributor, raises concerns about the company's long-term cash flow stability [1] - The company has exited a partnership that previously provided nearly 25% of its investment income in 2023 [1] - Both asset sales were executed at a 35% premium, but market sentiment remains cautious regarding future cash flow [1] Product Performance - Traditional Chinese medicine accounts for 91.47% of the company's revenue, with "Suoxiao Jiuxin Wan" showing only a slight sales increase of 5.45% to 1.128 billion yuan [1] - The promising "Qingyan Diban" product saw a substantial increase of 52.28% to 289 million yuan, but its small scale limits its impact [1] Compliance and Quality Issues - The company has faced multiple quality compliance issues, including penalties for substandard products and GMP deficiencies reported by the FDA [2] - Complaints related to quality, marketing, and after-sales service have exceeded 20 since 2025 [2] - The company's "slimming strategy" has led to short-term financial gains but has also resulted in weakened revenue-generating capabilities and cash flow [2] Strategic Challenges - The company is experiencing a lack of new product development to replace declining sales from its flagship products [2] - The lengthy innovation cycle in traditional Chinese medicine poses challenges for immediate revenue recovery [2] - The need for a return to product innovation and compliance is emphasized as essential for sustainable growth [2]

Core Viewpoint - Hainan Huhuwawa Pharmaceutical Group Co., Ltd. faces significant internal control issues, leading to a negative audit opinion and a stock trading suspension, with a change in stock abbreviation to "ST Huhuwawa" starting April 30, 2025 [1][3][5] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.414 billion yuan, a year-on-year decrease of 21.26%, and a net profit attributable to shareholders of -274 million yuan, a staggering decline of 2629.23% [10] - In the first quarter of 2025, the company achieved a revenue of 337 million yuan, down 28.42% year-on-year, with a net profit of approximately 24.35 million yuan, a decrease of 11.23% [10] Internal Control Issues - The audit report from Lixin Certified Public Accountants highlighted three major areas of concern regarding internal controls, including the lack of complete financial data related to restated financial statements and issues with accounts receivable from key clients [3][5] - The company has been criticized for significant deficiencies in its internal control over financial reporting, resulting in a negative opinion from the auditors [5] Management Changes - The company's general manager, Zhang Mingrui, resigned for personal reasons less than two months after taking office, marking a period of instability in leadership [2][6] - This resignation follows the earlier departure of Liu Jingping from the general manager position, who remains as chairman and has been a key figure in the company since its inception [7][8] Related Transactions - In 2024, the company purchased eight R&D projects from Hainan Zhongwang Medical Technology Development Co., Ltd. for 42.0537 million yuan, raising concerns due to familial ties between the company's actual controller and the legal representative of the vendor [4]